Fighting obesity and associated risk factors by antagonising cannabinoid type 1 receptors.
Pagotto
Uberto
U
Endocrine Unit, Department of Internal Medicine and Gastroenterology, and Center for Applied Biomedical Research, S Orsola-Malpighi General Hospital, Università Alma Mater Studiorum, Bologna 40138, Italy. pagube@med.unibo.it
Pasquali
Renato
R
D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D008055:Lipids / Q000097:blood; D009765:Obesity / Q000150:complications / Q000188:drug therapy*; D010880:Piperidines / Q000627:therapeutic use*; D011720:Pyrazoles / Q000627:therapeutic use*; D043884:Receptor, Cannabinoid, CB1 / Q000037:antagonists & inhibitors*; D000077285:Rimonabant; D012307:Risk Factors
D008055:Lipids; D010880:Piperidines; D011720:Pyrazoles; D043884:Receptor, Cannabinoid, CB1; D000077285:Rimonabant